



IMS Health & Quintiles are now



The potential of South East Asia and India as the hub for vaccine studies

Angela Chen
Therapeutic Strategy Lead

16 November 2017

Table of Contents

The potential of South East Asia and India (SEAI) as the frontier for vaccine studies

- + Current landscape of vaccine studies
- + The next hub for vaccine studies
- + Potential of SEAI
- + Better Asia public health

Analysts and experts observed the shift



BioTech (/category/bio-tech) > Vaccines (/category/vaccines) > 'Asia is the fastest growing vaccine market in the world'


'Asia is the fastest growing vaccine market in the world'

14 August 2017 | Opinion | By Aishwarya Venkatesh

Asian governments are striving to ensure that every stratum of the society, irrespective of social and economic status is granted access to immunization. In May 2012, the WHO launched the 'Global Vaccine Action Plan (GVAP)' that was authorized. High awareness levels of the benefits of immunization are the main drivers of the market. Associate Therapeutics Strategy Lead, Vaccines and Infectious Diseases, IQVIA.


Tweet

Market forecast for global vaccines market




“ The recent growth reports (such as that from Market Data Forecast Report and Global Research Market press release) shared that the vaccine market has a global growth of approximately 13% in which Asia region had been consistently reported as the fastest growing region in this segment at 20-30% year on year. “



Over the past 4 years, Asia participated in 31% of the 1170 vaccine studies and contributed ~60% of subjects




Illustrative example of global regulators approved rotavirus vaccines availability in national immunization programs



Asia Emerging Biopharmas are the key players in the Infectious Disease and Vaccine (IDV) market contributing ~130 new IDV per year



SEAI is the second largest contributor of subjects in studies involving Asia



Question: How is SEAI helpful to the vaccine development programs?

SEAI offers unique opportunities for vaccine studies

Singapore, Malaysia

- Short clinical study startup timeline
- Established regulatory guidelines
- Stable city infrastructure
- Highly experienced Investigators


Vietnam, Philippines, Thailand






- Large pool of healthy adults and pediatric volunteer
- Unique subject outreach structure
- High prevalence of tropical diseases
- Moderate national vaccination program coverage

India

- Good commercial and R&D market
- Low national vaccination program coverage
- High subject acceptance to me-too and me-similar vaccines

There are FIVE success driving factors in SEAI...



1	 Large Patient Pool	<ul style="list-style-type: none">• Genetically diverse and treatment/vaccine naive population• High incidence of tropical disease
2	 Cost Effectiveness	<ul style="list-style-type: none">• High cost effectiveness• Cost of running trials in SEAI is 40-60% lower than the US/Canada region
3	 Gateway to rest of Asia	<ul style="list-style-type: none">• Establishing a foothold in SEAI can provide access and synergies with the rest of Asia
4	 Public Health Focused	<ul style="list-style-type: none">• ASEAN committee made public health a priority since the 90s• Poorer Public Health reimbursement program hence naïve subjects
5	 Perception of Public	<ul style="list-style-type: none">• Positive perception towards vaccines• Harmonization of new vaccine regulations across region likely to happen in the next future

Question: How can we work together to improve public health in SEAI and also achieve the goal of your vaccine development program?

Think differently with real world data for better decision making



Rethinking
design



Truly targeted
Site and Patients




More effective
recruitment




Discover a more **precise path** to product approval and increase vaccine uptakes appropriately.

Connecting with the right data sources becomes important for protocol designing



An illustrative example of analytics output:



Conclusion

- Conducting studies within SEAI enables larger group of subjects immunized against common diseases
- SEAI government authorities are supportive of public health improvement programs
- SEAI local culture and beliefs fuel higher acceptance on vaccine studies
- Potential of real world data provides insights for better decisions to be made
- Lowest cost of clinical studies as compared to rest of the world



Thank you!